ClinVar Miner

Submissions for variant NM_000558.5(HBA1):c.178G>C (p.Gly60Arg)

dbSNP: rs281864895
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Quest Diagnostics Nichols Institute San Juan Capistrano RCV001283978 SCV001469511 pathogenic not provided 2020-02-14 criteria provided, single submitter clinical testing Predicted to have a damaging effect on the protein. One other pathogenic variant affects the same amino acid. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. Assessment of experimental evidence suggests this variant results in abnormal protein function.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003331101 SCV004037694 pathogenic alpha Thalassemia 2023-08-29 criteria provided, single submitter clinical testing Variant summary: HBA1 c.178G>C (p.Gly60Arg) results in a non-conservative amino acid change located in the Globin domain (IPR000971) of the encoded protein sequence. Four of four in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 7.4e-06 in 135930 control chromosomes (gnomAD). c.178G>C has been reported in the literature in multiple individuals affected with Alpha Thalassemia (e.g. Oron-Karni_2000, Fang_2014, Jiang_2017, Gilad_2017). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. However, in silico protein folding models predict that the variant is unstable in both oxy and de-oxy environments (Scheps_2019). The following publications have been ascertained in the context of this evaluation (PMID: 24261598, 28160324, 29115167, 11074535, 31553106). One ClinVar submitter has assessed the variant since 2014, and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.